Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;63(4):634-9.
doi: 10.1002/pbc.25862. Epub 2016 Jan 12.

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group

Michael A Arnold  1   2 , James R Anderson  3 , Julie M Gastier-Foster  1   2 , Frederic G Barr  4 , Stephen X Skapek  5 , Douglas S Hawkins  6   7 , R Beverly Raney Jr  8 , David M Parham  9 , Lisa A Teot  10 , Erin R Rudzinski  11 , David O Walterhouse  12
Affiliations

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group

Michael A Arnold et al. Pediatr Blood Cancer. 2016 Apr.

Abstract

Background: Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) is of prognostic and therapeutic importance. Criteria for classifying these entities evolved significantly from 1995 to 2013. ARMS is associated with inferior outcome; therefore, patients with alveolar histology have generally been excluded from low-risk therapy. However, patients with ARMS and low-risk stage and group (Stage 1, Group I/II/orbit III; or Stage 2/3, Group I/II) were eligible for the Children's Oncology Group (COG) low-risk rhabdomyosarcoma (RMS) study D9602 from 1997 to 1999. The characteristics and outcomes of these patients have not been previously reported, and the histology of these cases has not been reviewed using current criteria.

Procedure: We re-reviewed cases that were classified as ARMS on D9602 using current histologic criteria, determined PAX3/PAX7-FOXO1 fusion status, and compared these data with outcome for this unique group of patients.

Results: Thirty-eight patients with ARMS were enrolled onto D9602. Only one-third of cases with slides available for re-review (11/33) remained classified as ARMS by current histologic criteria. Most cases were reclassified as ERMS (17/33, 51.5%). Cases that remained classified as ARMS were typically fusion-positive (8/11, 73%), therefore current classification results in a similar rate of fusion-positive ARMS for all clinical risk groups. In conjunction with data from COG intermediate-risk treatment protocol D9803, our data demonstrate excellent outcomes for fusion-negative ARMS with otherwise low-risk clinical features.

Conclusions: Patients with fusion-positive RMS with low-risk clinical features should be classified and treated as intermediate risk, while patients with fusion-negative ARMS could be appropriately treated with reduced intensity therapy.

Keywords: D9602; D9803; alveolar rhabdomyosarcoma; embryonal rhabdomyosarcoma; fusion status; histology; low risk; outcomes; rhabdomyosarcoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: The authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Histologic heterogeneity among D9602 cases previously classified as ARMS. Cases enrolled in D9602 included classic ARMS (A, 40× objective magnification) and ARMS with regions of dense sclerosis (B, 40× objective magnification). Variants of ERMS included typical (C, 40× objective magnification), dense (D, 40× objective magnification), sclerosing (E, 40× objective magnification) and spindled patterns (F, 40× objective magnification). Mixed RMS typically featured distinct areas of ERMS and ARMS (G, 4× objective magnification; H upper left ERMS, 40× objective magnification; H lower right ARMS, 40× objective magnification).
Figure 2
Figure 2
ERMS with a PAX3-FOXO1 fusion. The histologic features of this case were variable, including a predominant spindle cell pattern (A, 40× objective magnification) with areas of dense ERMS (B, 40× objective magnification). Focal areas showed microalveolar architecture (C, 40× objective magnification). Myogenin IHC performed with this case showed strong (3+) nuclear reactivity (D, 40× objective magnification).
Figure 3
Figure 3
Event-Free Survival for ARMS with low-risk clinical features by patient age, combined D9602 and D9803 cases (n=66).
Figure 4
Figure 4
Event-Free Survival for ARMS with low-risk clinical features by FOXO1 fusion status, combined D9602 and D9803 cases (n=66).
See this image and copyright information in PMC

References

    1. Newton WA, Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Tsokos MG, Shimada H, Harms D, Schmidt D, Ninfo V, Cavazzana AO, Gonzalez-Crussi F, Parham DM, Reiman HM, Asmar L, Beltangady MS, Sachs NE, Triche TJ, Maurer HM. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. Cancer. 1995;76(6):1073–1085. - PubMed
    1. Barr FG, Smith LM, Lynch JC, Strzelecki D, Parham DM, Qualman SJ, Breitfeld PP. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J Mol Diagn. 2006;8(2):202–208. - PMC - PubMed
    1. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002;20(11):2672–2679. - PubMed
    1. Rudzinski ER, Teot LA, Anderson JR, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Am J Clin Pathol. 2013;140(1):82–90. - PMC - PubMed
    1. Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011;29(10):1312–1318. - PMC - PubMed

Publication types

Substances